NCT06736418View on ClinicalTrials.gov

Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy

PHASE1RecruitingINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

March 10, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

January 31, 2027

Conditions
Small-Cell Lung Cancer (SCLC)Large Cell Neuroendocrine Carcinoma of the Lung
Interventions
DRUG

225Ac-ABD147

A delta-like ligand 3 (DLL3)-targeting antibody fragment conjugated with a linker-chelator that effectively coordinates Ac-225

Trial Locations (5)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

21061

RECRUITING

United Theranostics, Glen Burnie

77030

RECRUITING

MD Anderson, Houston

84112

RECRUITING

Huntsman Cancer Institute, Salt Lake City

92663

RECRUITING

Hoag Memorial Hospital Presbyterian, Newport Beach

Sponsors
All Listed Sponsors
lead

Abdera Therapeutics Inc.

INDUSTRY